CD274 and neoplasm: In line with this, the study presented in a Mini Oral Session at the ESMO (European Society for Medical Oncology) Targeted Anticancer Therapies Congress 2022 [68] demonstrated significant tumor regression in mouse SCLC models when AZD1775 and anti-PD-L1 inhibition were combined.